Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Novartis
Novartis
Kivu Bioscience Inc.
City of Hope Medical Center
University of California, Irvine
M.D. Anderson Cancer Center
ViroMissile, Inc.
AstraZeneca
Washington University School of Medicine
Essen Biotech
MacroGenics
Alliance for Clinical Trials in Oncology
University of Nebraska
Adela, Inc
Perspective Therapeutics
Var2 Pharmaceuticals
UNICANCER
Memorial Sloan Kettering Cancer Center
Tanabe Pharma America, Inc.
Tango Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Hadassah Medical Organization
British Columbia Cancer Agency
Washington University School of Medicine
Epkin
Guangzhou FineImmune Biotechnology Co., LTD.
GONGCHU Biotechnology Co., Ltd
Jonsson Comprehensive Cancer Center
Turning Point Therapeutics, Inc.
University of Pittsburgh
University of California, Irvine
Cancer Research UK
Institut du Cancer de Montpellier - Val d'Aurelle
Stanford University
BostonGene
Second Affiliated Hospital of Guangzhou Medical University
Innolake Biopharm